Key information

🔎 Fund Overview

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company. The Company is engaged in developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. It is using its proprietary DIAMOND artificial intelligence (AI) 2.0 platform to discover targets for immuno-oncology. It has five clinical programs to study its key product candidates: Deltacel-01, Isocel combination, Alexis-ISO-1, Procel combination, and Alexis-PRO-1. Deltacelis its first allogeneic, off-the-shelf GDT cell-based product in Phase 1 clinical-stage. Its Procel and Isocel product candidates consist of allogeneic, engineered, off-the-shelf CAR-GDT cells, and they are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs that target PD-L1. Isocel product candidate consists of engineered GDTs that target Mesothelin Isoform 2 positive tumors (Iso-Meso).